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Background: Our objective was to assess longitudinal health-related quality of life (HRQoL) in patients treated with
radiotherapy for gynecologic malignancy and assess the relationship of psychosocial encounters on HRQoL.
Methods: Women with gynecologic malignancy were prospectively enrolled and HRQoL assessed before, during,
and after radiotherapy treatment using validated measures. Treatment and demographic information were
reviewed. Mixed-effects models were used to assess changes in quality of life (QoL) over time and association of
psychologist and social worker encounters with overall QoL as well as subdomains of QoL.
Results: Fifty-two women were enrolled and 41 completed at least one assessment. Fatigue (p = 0.008), nausea
(p = 0.001), feeling ill (p = 0.007), and being bothered by side effects (p < 0.001) worsened on treatment with
subsequent improvement. By follow-up, patients reported increased functional well-being (FWB) with significant
decrease in worry (p = 0.003), increase in enjoyment of things usually done for fun (p = 0.003) and increase in
contentment (p = 0.047). Twenty-three patients had at least one interaction with a social worker or psychologist
during treatment. Each additional interaction was associated with a 2.12 increase in FWB score from before to after
treatment (p = 0.002), and 1.74 increase from on to after treatment (p = 0.011). Additional interactions were not
significantly associated with changes in overall FACT score (p = 0.056) or SWB (p = 0.305).
Conclusions: Patient-reported HRQoL significantly worsened during radiotherapy treatment with subsequent
improvement, affirming transiency of treatment-induced toxicities. Our preliminary study suggests that clinically-
recommended psychological and social work interventions have potential value with respect to improving patient
QoL during radiotherapy. Larger studies are needed to validate our findings.
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As gynecological cancer patients live longer due to im-
proved therapies, studies have reported that many survi-
vors experience significant long-term sequelae from
their cancer and treatment that can significantly impact
their health related quality of life (HRQoL) [1,2]. HRQoL
has been found to significantly affect patient’s survivor-
ship experiences, adherence to subsequent treatment,* Correspondence: lin@xrt.upenn.edu
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unless otherwise stated.and even predict survival after controlling for demo-
graphic and clinical characteristics [3,4]. Capturing pa-
tients’ macro state of well-being through HRQoL is also
important to better and more holistically measure and
understand the effectiveness of treatment beyond patient
survival.
Treatment of gynecologic malignancies often involves
a multi-modality approach and is associated with high
morbidity and changes in bowel, bladder, hormonal, sex-
ual, and reproductive function, many of which can cause
emotional and psychosocial in addition to physical dis-
tress [1,5]. Poor psychosocial adjustment in patients withhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in particular, as well as with multi-modality treatment,
younger patient age, longer treatment duration, disen-
gaged coping style, and inadequate social support [1].
QoL of gynecologic cancer patients tends to be at its
worst between time of diagnosis and completion of radio-
therapy [1]. When patients treated for gynecologic cancer
were surveyed and asked to rate their emotional distress
while on treatment, 57% reported needing help dealing
with emotional problems, suggesting a high prevalence of
potential need for additional psychosocial support [6]. The
duration between initial diagnosis and on-treatment is also
the time when oncologists interact most with the patient,
and provides the greatest opportunity for intervention.
Therefore, it is important to study the emotional and
functional components of QoL in gynecologic cancer pa-
tients while on active treatment, a critical window for add-
itional clinician support. Previous studies suggest that
psychosocial interventions for cancer patients in the acute
setting improve patients’ psychological well-being [7-9].
Because radiation therapy has been associated with risk of
poor adjustment, our objective was to identify the trajec-
tory of patients’ quality of life (QoL) during and after
radiotherapy, particularly the role of psychosocial interac-
tions on patient QoL.
Characterization of gynecologic cancer patient-reported
QoL over the treatment course may more effectively and
appropriately identify patients with substantial emotional
support needs who may benefit most from a social worker
or psychologist referral. This study assesses longitudinal
QoL and investigates psychosocial encounters as a pre-
dictor for improved QoL among patients with gynecologic
cancer receiving radiation therapy. We hypothesized that




Women with gynecologic malignancies undergoing radi-
ation therapy (RT) with or without systemic therapy were
prospectively enrolled in an IRB approved prospective
clinical study to assess HRQoL between 2009 and 2012 at
University of Pennsylvania (PENN). This QOL study was
open to all patients receiving radiotherapy at PENN re-
gardless of primary disease site as long as the treatment
was with definitive curative intent. Patients were recruited
either at the time of consultation or at the time of simula-
tion for radiotherapy treatment planning. The protocol for
data collection, storage and retrieval complied with the
PENN Institutional Review Board and Health Insurance
Privacy and Portability Act regulations. QoL assess-
ments were collected pre-RT, during RT, and within
3 months post-RT using MD Anderson Symptom In-
ventory (MDASI) and Functional Assessment of CancerTherapy-General (FACT-G). Eligibility criteria included
age 18 and above and ability to read and understand
English. Patient-reported QoL assessments were matched
and compared with specific, corresponding outcomes
extracted from physician encounter notes from corre-
sponding time points. Diagnosis, treatment modality,
concurrent chemotherapy treatment and demographics
were also reviewed.
Measures of QoL
HRQoL surveys were obtained at baseline, during, and
approximately 3 months after RT using the following
validated measures:
MD Anderson Symptom Inventory (MDASI)
The MDASI is a 26-item questionnaire assessing core
symptom severity and interference with life activities. In
the first part, patients rate the severity of symptoms
experienced in the last 24 hours on a 0–10 scale with 0
being not present and 10 being “as bad as you can im-
agine”. The second part entails rating how symptoms
have interfered with various life activities, mood, and life
enjoyment on a 0–10 scale, with 0 being “did not inter-
fere” and 10 being “interfered completely”. Due to the
larger number of items included in the MDASI, we
focused on selected MDASI core items based on com-
monly occurring symptoms among patients in this
population, namely pain, fatigue, disturbed sleep, dis-
tressed, difficulty remembering things, lack of appetite,
sadness and drowsiness.
Functional Assessment of Cancer Therapy-General (FACT-G)
The FACT-G was developed for cancer patients with
cancer at various sites, and its reliability and validity has
been reported [10]. FACT-G is scored by aggregating the
individual scale scores, with higher scores indicating bet-
ter quality of life. The FACT-G is a commonly used tool
measuring general quality of life across four subscales:
physical well-being (7 items), social/family well-being (7
items), emotional well-being (6 items), and functional
well-being (7 items). The patient is asked to grade their
response as it applies to the past 7 days on 5 levels in-
cluding: 0-not at all, 1-a little bit, 2-somewhat, 3-quite a
bit, and 4-very much. Physical well-being (PWB) in-
cludes lack of energy, nausea, trouble meeting needs of
family, pain, being bothered by side effects of treatment,
feeling ill, and being forced to spend time in bed. Social/
family well-being (SWB) includes feeling close to and
getting emotional support from family and/or friends,
being satisfied with family communication about the pa-
tient’s illness, satisfaction with sex life, and feeling close
to a partner or main support. Emotional well-being
(EWB) includes feeling sad, being satisfied with coping,
losing hope, feeling nervous, worrying about dying, and
Table 1 Patient characteristics
n (%)
Number of patients completed assessments/included 41













Radiation technique, n (%)
IMRT 10 (24.4)
Brachytherapy 12 (29.3)
Both IMRT and Brachytherapy 19 (46.3)
Systemic therapy, n (%)
None 17 (41.5)
Chemotherapy 24 (58.5)
Previous radiation therapy 0
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being (FWB) includes being able to work (including
work at home) and find work fulfilling, enjoying life,
accepting illness, sleeping well, enjoying things usually
done for fun, and being content with QoL. Each FACT-
G subscale is independently scored (on a scale of 0–28,
except EWB 0–24) and also contributes to a total
FACT-G cumulative score (scale of 0–108, higher score
indicates better QoL).
Medical and demographic characteristics
Clinical data were abstracted from patients’ electronic
medical records. Other data collected included patient
age, race, ethnicity, cancer type, stage at diagnosis, radi-
ation technique and dose, history of prior radiation
therapy, and receipt of systemic therapy. Psychosocial en-
counters were grouped as psychosocial support, financial
resource assistance, cancer center counseling, or allied
health coordination (including lodging/transportation/in-
surance/employment) by reviewing the patient medical
records.
Statistical analyses
Descriptive statistics of HRQoL and medical factors
were summarized for study participants. Comparisons
between the subjects included and excluded from the
final analyses were performed using the Wilcoxon rank
sum test for continuous variables and Fisher’s exact test
for categorical variables. Mixed-effects models with pa-
tient random effect including adjustment for time were
used to analyze change in patient-reported QoL and
symptoms over the treatment course. Time (pre-, on-,
post-RT) was treated as categorical. Mixed-effects models
were also used to analyze effect of number of encounters
with psychologists and social workers on changes in func-
tional quality of life. These models were adjusted for pa-
tient age, malignancy type, and body mass index. All
mixed-effects models assume correlation between all mea-
surements on the same subject, and that the correlation
was the same for all pairs of time points. All statistical
analyses were conducted using SAS 9.3 (SAS Institute,
Cary, NC) with a two-sided Type I error rate of 0.05.
Results
Patient demographics
Fifty-two gynecologic cancer patients were enrolled, of
whom 41 patients completed at least one QoL assess-
ment. Eleven patients were enrolled but did not have an
initial evaluation or complete subsequent assessments
and were excluded from subsequent analyses. Compari-
sons between included (N = 41) and excluded (N = 11)
subjects indicated that the two groups did not differ in
terms of demographic characteristics such as age (p =
0.771) and BMI (p = 0.638) or clinical characteristicssuch as stage (p = 0.192), radiation technique (p = 0.198),
and cancer type (p = 0.449). Of 41 patients included in
the analyses, 25 patients had endometrial cancer, 14 had
cervical cancer, 1 had vaginal cancer, and 1 had vulvar
cancer (Table 1). The median patient age was 61 (range,
33–74). At diagnosis, 58.3% of patients were stage I,
19.4% stage II, 19.4% stage III, and 3% stage IV. Twenty-
four patients had chemotherapy, either sandwich or
concurrently with RT. For RT treatment, 10 patients re-
ceived IMRT only, 12 received brachytherapy only, and
19 received both IMRT and brachytherapy. None of the
patients had history of prior radiation therapy for gyne-
cologic malignancy.
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Age, employment status, marital status, ECOG, cancer
type, chemotherapy, and cancer stage were not predict-
ive of baseline FACT-G QoL scores at the 0.05 signifi-
cance level.
Changes in patient-reported symptoms over time
Table 2 presents the mean scores of FACT-G subscales
and selected MDASI core items at each assessment time
point in aggregate and by treatment modality. Overall,
the changes in scores over time were significant in
FACT-G total (p = 0.006), PWB (p < 0.001) and FWB
(p = 0.004) (Figure 1). Specifically, there were significant
improvements from on-RT to follow-up FACT-G total
(slope, 9.93; p = 0.001), PWB (5.86; p < 0.001) and FWB
(3.75; p = 0.001). PWB significantly worsened from pre-
RT to on-RT (−4.07, p < 0.001), while FWB significantly
increased between pre-RT and follow-up (2.41, p =
0.026). FACT-G patient-reported fatigue increased from
before to on-treatment (p = 0.008) and subsequently de-
creased after treatment (p = 0.009). Patient-reported nau-
sea (p = 0.001), feeling ill (p = 0.007), and being bothered
by side effects of treatment (p < 0.001) on the FACT-G
all increased on treatment and decreased after treat-
ment. However, patients reported “having increased
trouble meeting the needs of their families” from on-
treatment to follow-up on the FACT-G (p = 0.012).
From pre-treatment to follow-up, patients reported a
significant decrease in worry that their condition will
worsen (p = 0.003), increase in enjoyment of things usu-
ally done for fun (p = 0.003) and increase in contentment
with quality of life on the FACT-G (p = 0.047). Patients
report an increased ability to enjoy their lives after treat-
ment compared to when they were on treatment on the
FACT-G (p = 0.012).
Significant changes in MDASI patient-reported symp-
toms were fatigue (p = 0.002) and drowsiness (p = 0.006),
which both increased during treatment but did not sig-
nificantly decrease by follow up.
Effect of patient interaction with social workers or
psychologists on change in quality of life over time
Twenty-three of the 41 patients had at least one inter-
action with a social worker or psychologist during radi-
ation therapy. Total number of interactions ranged from
one to six (median = 1). Thirteen patients had 1 inter-
action, 3 patients had two visits, 2 patients had 3 visits,
and 5 patients had 4 or more encounters. Encounters in-
cluded social/emotional support (27), financial resource
assistance (5), cancer center counseling (4), allied health
coordination/lodging/transportation/employment issues
(11). Patient interaction with social workers and psychol-
ogists was predictive of improved patient functional
quality of life post treatment compared to pre- and on-treatment as measured by the functional well-being sub-
score (Table 3). After adjusting for age, cancer type and
BMI, each additional interaction with a social worker or
psychologist was associated with an increase of 2.12
points in the FWB score from before to after treatment
(p = 0.002), and an increase of 1.74 points from on to
post-RT (p = 0.011). Additional interactions were not
significantly associated with changes in overall FACT
score (p = 0.056), or other subscores (SWB (p = 0.305),
PWB (p = 0.271), EWB (p = 0.569). Figure 2 displays an
example of the trajectory of FACT-G FWB for patients
(with median age of 61, BMI < 25 with cervical cancer)
from pre- to post-RT by the number of interactions with
social workers and psychologists derived from the
model-based estimates of the mixed-effects model.
Discussion
Our analysis found that gynecologic cancer patients at
our institution reported significant improvement in psy-
chological QoL measures as measured by FWB subscore
from before treatment to follow-up. Patients reported
decreased worry in their condition worsening, increase
in enjoyment of things usually done for fun, and increase
in contentment with quality of life. These positive psy-
chological changes could be due to either treatment
effect or effective counseling by the physician, and thus
are important for adequate valuation of HRQoL for
future cost-utility analyses and treatment effectiveness
analyses capturing the macro state of patient health.
Our analysis examined the impact of one particular
type of intervention that could have contributed to the
positive psychological changes in our patients: clinician-
recommended patient encounters with social workers
and psychologists. Interestingly, we found that each add-
itional interaction with a social worker or psychologist
was associated with a 2.12 point increase in functional
well-being subscore from before to after treatment (p =
0.002). The functional well-being subscore includes “en-
joyment of things usually done for fun”, and “increase in
contentment with quality of life”, two of three psycho-
logical QoL measures that we previously identified as
significantly improved in our patients over the course of
study. No study to our knowledge has previously vali-
dated the benefit of psychological and social work inter-
vention on quality of life specifically in gynecological
cancer patients undergoing radiation therapy. Our study
suggests that these types of interventions may indeed in-
crease value with respect to patient quality of life during
radiotherapy.
There are inherent limitations to our study including
the limited number of study patients and heterogeneity
of sites of malignancy (Table 1), oncologic treatments
(brachytherapy, external beam radiotherapy) as well as
in the types of psychosocial interactions. Also, although
Table 2 Summary of FACT-G and MDASI scores
Radiation technique




N Mean (SD) N Mean (SD) N Mean (SD)
FACT-G total and subscale scores*
Total FACT-G
Pre 33 80.4 (20.8) 23 81.1 (20.0) 10 78.6 (23.7)
On 30 78.5 (22.2) 22 77.4 (23.0) 8 81.4 (21.0)
Post 27 84.7 (17.6) 21 86.9 (17.5) 6 77.1 (17.5)
Physical well-being
Pre 33 21.4 (6.9) 23 21.5 (6.6) 10 21.3 (7.9)
On 30 18.3 (8.1) 22 17.6 (8.5) 8 20.2 (6.8)
Post 27 22.5 (5.9) 21 23.4 (5.3) 6 19.5 (7.4)
Social well-being
Pre 33 23.6 (4.4) 23 23.8 (4.5) 10 23.0 (4.3)
On 30 24.4 (4.5) 22 24.1 (4.9) 8 25.3 (3.1)
Post 27 23.2 (5.9) 21 23.3 (6.4) 6 22.8 (4.2)
Emotional well-being
Pre 33 17.4 (5.4) 23 17.8 (5.5) 10 16.5 (5.1)
On 30 18.1 (5.4) 22 18.2 (5.5) 8 17.9 (5.7)
Post 27 19.1 (3.9) 21 19.3 (3.9) 6 18.5 (4.1)
Functional well-being
Pre 33 18.0 (6.7) 23 18.0 (6.5) 10 17.8 (7.5)
On 30 17.6 (7.6) 22 17.5 (7.9) 8 18.0 (7.5)
Post 27 19.9 (7.0) 21 20.9 (7.0) 6 16.3 (6.3)
Selected MDASI core-items**
Pain
Pre 32 1.5 (2.7) 22 1.4 (2.7) 10 1.8 (2.6)
On 28 1.7 (2.5) 21 2.1 (2.8) 7 0.4 (0.8)
Post 27 1.1 (2.3) 21 0.7 (1.2) 6 2.8 (4.2)
Fatigue
Pre 33 2.2 (2.5) 23 1.6 (1.9) 10 3.5 (3.2)
On 29 3.9 (2.6) 21 4.2 (2.8) 8 3.0 (2.1)
Post 27 3.3 (3.2) 21 2.7 (2.9) 6 5.5 (3.7)
Sleep
Pre 33 2.5 (3.1) 23 2.3 (2.8) 10 3.0 (3.9)
On 28 2.4 (2.8) 20 2.6 (2.9) 8 1.8 (2.8)
Post 27 2.9 (3.3) 21 2.5 (3.0) 6 4.0 (4.4)
Upset
Pre 33 3.0 (3.0) 23 3.0 (2.9) 10 2.9 (3.5)
On 28 2.1 (2.8) 20 2.3 (3.2) 8 1.8 (1.7)
Post 27 2.7 (3.4) 21 2.4 (3.1) 6 3.5 (4.4)
Memory
Pre 31 1.7 (2.7) 21 1.4 (2.2) 10 2.3 (3.7)
On 29 1.1 (1.2) 21 1.1 (1.3) 8 1.1 (1.1)
Post 26 2.2 (2.5) 20 2.1 (2.3) 6 2.5 (3.2)
Table 2 Summary of FACT-G and MDASI scores (Continued)
Appetite
Pre 33 1.3 (2.5) 23 0.9 (1.6) 10 2.2 (3.7)
On 29 1.8 (2.2) 21 1.9 (2.3) 8 1.6 (1.9)
Post 27 1.2 (2) 21 0.9 (1.7) 6 2.5 (2.6)
Sad
Pre 33 2.8 (3.5) 23 2.7 (3.5) 10 3.0 (3.7)
On 29 2.1 (2.6) 21 2.2 (2.7) 8 1.9 (2.6)
Post 27 2.3 (2.5) 21 2.0 (2.3) 6 3.3 (3.1)
Drowsy
Pre 33 1.5 (2.4) 23 0.9 (1.3) 10 2.7 (3.6)
On 29 2.8 (2.8) 21 2.9 (2.9) 8 2.5 (2.6)
Post 27 2.7 (3.1) 21 2.4 (2.7) 6 3.7 (4.2)
*FACT-G: higher score implies higher level of HRQoL.
**MDASI: lower score implies higher level HRQoL.
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prehensive information regarding support systems at
home which may be a confounding factor. Additionally,
this study was not designed or powered to establish a
causal relationship between number of psychosocial in-
teractions and quality of life. We recognize the potential
inflation of Type I error or false-positive results due to
multiple testing and the possibility of spurious associa-
tions from the study from the many comparisons made.
As noted, this set of analyses is part of a larger study
intended as hypothesis-generating and requires valid-
ation in larger studies specifically designed to evaluate
the impact of psychosocial encounters on quality of life
in gynecologic cancer patients. Attention towards the
impact of psychosocial distress on quality of life has
been increasingly recognized as emerging research sug-
gests that methods that screen for and address distress
improves quality of life, but may also be associated with
improved cancer outcomes [11,12]. The American Col-
lege of Surgeons Commission on Cancer beginning in
2015 will require that cancer centers implement screen-
ing programs for psychosocial distress as a requirement
for accreditation [13].
Patient-reported HRQoL may be useful for identifying
patients who can benefit from additional support before
and during treatment. We found that patient-reported
HRQoL significantly decreased while on treatment, but
subsequent improvement of nearly all measures oc-
curred in the period from end of treatment to follow-
up. Therefore, our study using patient-reported QoL
supports the transiency of acute radiotherapy toxicity.
However, prior studies have identified treatment with
radiotherapy as a significant risk factor for maladjustment
in gynecologic cancer patients, particularly cervical cancer
patients, exacerbated by increased length of treatment,
younger patient age, and greater treatment toxicity
Table 3 Mixed-effects model: effects of psychosocial
encounters and time on Functional well-Being (FWB)






Psychosocial 0.00 [1,34] −0.838
Psychosocial *Time 5.46** [2,45]
Psychosocial × Pre [Reference]
Psychosocial × On 0.376
Psychosocial × Post 2.115**
Age 0.60 [1,34] −0.078





BMI < 25 [Reference]
25 < =BMI < 30 −6.365*
30 < =BMI −0.227
*P < = 0.05.
**P < 0.01.
Figure 1 Change in gynecologic cancer patient Functional Assessment of Cancer Therapy-General (FACT-G) quality of life scores over
the treatment course, as compared to pre-treatment score.
Fang et al. Radiation Oncology  (2015) 10:34 Page 6 of 8[1,14-16]. Greimel et al. found that during active treat-
ment, gynecologic cancer patients had significantly
worse QoL particularly with respect to physical and
role function compared with breast cancer patients
[17]. Therefore, although acute toxicities are temporary,
they tend to be more severe for gynecologic patients
compared with breast cancer patients. Particularly for
gynecologic patients receiving radiotherapy, additional
psychosocial and emotional support before and during
treatment may be warranted [18].Figure 2 Improved trajectory of FACT-G Functional Well-Being
(FWB) from Pre/On/Post treatment with greater number of
interactions with social workers and psychiatrists (shown here
are estimated FWB scores for patients with median age 61,
BMI <25 with cervical cancer).
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can be effective in improving QoL during radiotherapy.
A recent randomized controlled trial compared 131
patients with advanced cancer actively undergoing RT
receiving either standard care or a structured, multidis-
ciplinary intervention involving six 90-minute sessions
led by a clinical psychologist or psychiatrist addressing 5
domains of QoL: emotional, social, cognitive, physical,
and spiritual [8]. Overall QoL of patients who received
the intervention was significantly higher than that of the
control arm as assessed by FACT-G at week 4 (p = 0.02).
Patients were able to maintain their baseline QoL score
as opposed to those in the control arm in whom QoL
decreased [8]. A social work component in structured
interventions for patients with advanced cancer im-
proved scores in the social domain of QoL, contributing
to clinically meaningful overall QoL improvement (p =
0.03) [9]. Wenzel et al. reported finding substantial pa-
tient interest in a counseling program to discuss psycho-
social issues [19]. Of the patients interviewed 5–10 years
after cervical cancer diagnosis, 69% stated they would
have participated in a psychosocial counseling program
had it been offered during their initial treatment [19].
Within the cancer center at the University of
Pennsylvania, we have a dedicated team of mental
health professionals trained to address the psycho-
social needs of cancer patients. Referrals are typically
made at patients’ request or initiated by nurses or phy-
sicians on the basis of clinical assessment while they
are receiving radiotherapy. An initial comprehensive
assessment of the patients’ social, emotional, physical,
psychological, and financial needs is completed either
via telephone or in person. Needs are prioritized and
resources are explored, which include emotional sup-
port/psychological counseling, transportation to and from
treatments, temporary lodging, clarification of insurance
benefits, accessing unemployment and disability coverage,
obtaining durable medical equipment, prescription pay-
ment assistance and accessing financial supports. Social
workers partner with local and national programs to con-
nect patients with programs that will assist with these
various needs. Patients can also access counseling and
management of mental health medications through refer-
rals to both community-based mental health professionals
and the Abramson Cancer Center’s cancer counseling ser-
vice, which includes a psychiatrist, psychiatric fellows and
licensed clinical social workers.
Our study affirms the importance of capturing patient-
reported HRQoL which will help identify and validate
other potential clinical recommendations and interven-
tions that can improve patient QoL over the course of
treatment. Increased gynecologic cancer patient inter-
action with social workers and psychologists was pre-
dictive of improved patient functional well-being QoLfrom the pre-treatment to on-treatment period. Further
studies of additional supportive psychosocial referrals
and interventions for gynecologic cancer patients receiv-
ing radiotherapy are warranted to assess for causal
impact.
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